Loading…
Interleukin‐22 serum levels are elevated in active scleritis
Purpose To evaluate serum cytokine profile from patients with active scleritis in a two‐centre prospective case–control study. Methods The serum of 20 active scleritis patients not treated with any local, periocular, or systemic immunomodulatory therapy (IMT) was analysed with multiplex assay to det...
Saved in:
Published in: | Acta ophthalmologica (Oxford, England) England), 2016-09, Vol.94 (6), p.e395-e399 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33 |
---|---|
cites | cdi_FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33 |
container_end_page | e399 |
container_issue | 6 |
container_start_page | e395 |
container_title | Acta ophthalmologica (Oxford, England) |
container_volume | 94 |
creator | Sainz‐de‐la‐Maza, Maite Molins, Blanca Mesquida, Marina Llorenç, Victor Zarranz‐Ventura, Javier Sala‐Puigdollers, Anna Matas, Jessica Adan, Alfredo Foster, C. Stephen |
description | Purpose
To evaluate serum cytokine profile from patients with active scleritis in a two‐centre prospective case–control study.
Methods
The serum of 20 active scleritis patients not treated with any local, periocular, or systemic immunomodulatory therapy (IMT) was analysed with multiplex assay to determine the levels of 11 cytokines interleukin (IL)‐1β, IL‐6, IL‐2, IFN‐γ, IL‐10, IL‐12p40, IL‐13, IL‐17A, IL‐5, TNF‐α, and TNF‐β, and with ELISA to determine the levels of TGF‐β1, IL‐22, and IL‐23. Twenty‐five age‐matched healthy volunteers were used as controls. In a subgroup of 13 patients with active disease, a second serum sample was obtained when the disease was inactive and levels of IL‐22 were determined. Serum IL‐22 levels from patients with active scleritis were correlated with type of scleritis (non‐necrotizing and necrotizing), degree of inflammation (0–4+ :≤2+ and >2+), and associated systemic disease.
Results
Serum levels of IL‐22 were elevated in active scleritis patients compared to controls (6.41 ± 1.52 pg/ml versus 1.93 ± 0.39 pg/ml, p = 0.012) and significantly decreased after scleritis remission with the use of IMT (p = 0.005). There was no statistical association with scleritis type, degree of inflammation, or associated systemic disease. The serum levels of other cytokines were not significantly different from controls.
Conclusion
In our study cohort, IL‐22 serum levels were significantly elevated in active scleritis patients compared to controls and decreased significantly after remission. Our results suggest that IL‐22, a T helper (Th) 17‐ and Th22‐ derived cytokine, may play a critical role in the physiopathology of scleritis. |
doi_str_mv | 10.1111/aos.13005 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1819142213</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1819142213</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33</originalsourceid><addsrcrecordid>eNqN0MtKw0AUBuBBFFurC19AAm50kXbumdkIpXgpFLpQwV2YJCeQmiZ1JlG68xF8Rp_EqaldCIJnc87i44fzI3RK8JD4GZnaDQnDWOyhPomECFkk1f7uFk89dOTcAmNJpOSHqEcjjDVTtI-uplUDtoT2uag-3z8oDRzYdhmU8AqlC4yFAPxtGsiCogpM2hSvELi0BFs0hTtGB7kpHZxs9wA93lw_TO7C2fx2OhnPwpRrIkLNaQ5KkogTyYWWIqWJzgjVBifAowg0JjqJMpZkOdUMeCK4wSrNJKgcA2MDdNHlrmz90oJr4mXhUihLU0HdupgoogmnlPyLCqlwJLCn57_oom5t5R_ZKK6YFEx5ddmp1NbOWcjjlS2Wxq5jguNN_7HvP_7u39uzbWKbLCHbyZ_CPRh14K0oYf13Ujye33eRX6A1jSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1814836538</pqid></control><display><type>article</type><title>Interleukin‐22 serum levels are elevated in active scleritis</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Sainz‐de‐la‐Maza, Maite ; Molins, Blanca ; Mesquida, Marina ; Llorenç, Victor ; Zarranz‐Ventura, Javier ; Sala‐Puigdollers, Anna ; Matas, Jessica ; Adan, Alfredo ; Foster, C. Stephen</creator><creatorcontrib>Sainz‐de‐la‐Maza, Maite ; Molins, Blanca ; Mesquida, Marina ; Llorenç, Victor ; Zarranz‐Ventura, Javier ; Sala‐Puigdollers, Anna ; Matas, Jessica ; Adan, Alfredo ; Foster, C. Stephen</creatorcontrib><description>Purpose
To evaluate serum cytokine profile from patients with active scleritis in a two‐centre prospective case–control study.
Methods
The serum of 20 active scleritis patients not treated with any local, periocular, or systemic immunomodulatory therapy (IMT) was analysed with multiplex assay to determine the levels of 11 cytokines interleukin (IL)‐1β, IL‐6, IL‐2, IFN‐γ, IL‐10, IL‐12p40, IL‐13, IL‐17A, IL‐5, TNF‐α, and TNF‐β, and with ELISA to determine the levels of TGF‐β1, IL‐22, and IL‐23. Twenty‐five age‐matched healthy volunteers were used as controls. In a subgroup of 13 patients with active disease, a second serum sample was obtained when the disease was inactive and levels of IL‐22 were determined. Serum IL‐22 levels from patients with active scleritis were correlated with type of scleritis (non‐necrotizing and necrotizing), degree of inflammation (0–4+ :≤2+ and >2+), and associated systemic disease.
Results
Serum levels of IL‐22 were elevated in active scleritis patients compared to controls (6.41 ± 1.52 pg/ml versus 1.93 ± 0.39 pg/ml, p = 0.012) and significantly decreased after scleritis remission with the use of IMT (p = 0.005). There was no statistical association with scleritis type, degree of inflammation, or associated systemic disease. The serum levels of other cytokines were not significantly different from controls.
Conclusion
In our study cohort, IL‐22 serum levels were significantly elevated in active scleritis patients compared to controls and decreased significantly after remission. Our results suggest that IL‐22, a T helper (Th) 17‐ and Th22‐ derived cytokine, may play a critical role in the physiopathology of scleritis.</description><identifier>ISSN: 1755-375X</identifier><identifier>EISSN: 1755-3768</identifier><identifier>DOI: 10.1111/aos.13005</identifier><identifier>PMID: 27009382</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; biomarker ; Case-Control Studies ; Cytokines ; Cytokines - blood ; Enzyme-Linked Immunosorbent Assay ; Female ; Health risk assessment ; Humans ; Interleukin-22 ; Interleukins - blood ; Male ; Middle Aged ; Ophthalmology ; Prospective Studies ; scleritis ; Scleritis - blood ; Scleritis - diagnosis ; Systemic diseases</subject><ispartof>Acta ophthalmologica (Oxford, England), 2016-09, Vol.94 (6), p.e395-e399</ispartof><rights>2016 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd</rights><rights>2016 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2016 Acta Ophthalmologica Scandinavica Foundation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33</citedby><cites>FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27009382$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sainz‐de‐la‐Maza, Maite</creatorcontrib><creatorcontrib>Molins, Blanca</creatorcontrib><creatorcontrib>Mesquida, Marina</creatorcontrib><creatorcontrib>Llorenç, Victor</creatorcontrib><creatorcontrib>Zarranz‐Ventura, Javier</creatorcontrib><creatorcontrib>Sala‐Puigdollers, Anna</creatorcontrib><creatorcontrib>Matas, Jessica</creatorcontrib><creatorcontrib>Adan, Alfredo</creatorcontrib><creatorcontrib>Foster, C. Stephen</creatorcontrib><title>Interleukin‐22 serum levels are elevated in active scleritis</title><title>Acta ophthalmologica (Oxford, England)</title><addtitle>Acta Ophthalmol</addtitle><description>Purpose
To evaluate serum cytokine profile from patients with active scleritis in a two‐centre prospective case–control study.
Methods
The serum of 20 active scleritis patients not treated with any local, periocular, or systemic immunomodulatory therapy (IMT) was analysed with multiplex assay to determine the levels of 11 cytokines interleukin (IL)‐1β, IL‐6, IL‐2, IFN‐γ, IL‐10, IL‐12p40, IL‐13, IL‐17A, IL‐5, TNF‐α, and TNF‐β, and with ELISA to determine the levels of TGF‐β1, IL‐22, and IL‐23. Twenty‐five age‐matched healthy volunteers were used as controls. In a subgroup of 13 patients with active disease, a second serum sample was obtained when the disease was inactive and levels of IL‐22 were determined. Serum IL‐22 levels from patients with active scleritis were correlated with type of scleritis (non‐necrotizing and necrotizing), degree of inflammation (0–4+ :≤2+ and >2+), and associated systemic disease.
Results
Serum levels of IL‐22 were elevated in active scleritis patients compared to controls (6.41 ± 1.52 pg/ml versus 1.93 ± 0.39 pg/ml, p = 0.012) and significantly decreased after scleritis remission with the use of IMT (p = 0.005). There was no statistical association with scleritis type, degree of inflammation, or associated systemic disease. The serum levels of other cytokines were not significantly different from controls.
Conclusion
In our study cohort, IL‐22 serum levels were significantly elevated in active scleritis patients compared to controls and decreased significantly after remission. Our results suggest that IL‐22, a T helper (Th) 17‐ and Th22‐ derived cytokine, may play a critical role in the physiopathology of scleritis.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>biomarker</subject><subject>Case-Control Studies</subject><subject>Cytokines</subject><subject>Cytokines - blood</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Interleukin-22</subject><subject>Interleukins - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Ophthalmology</subject><subject>Prospective Studies</subject><subject>scleritis</subject><subject>Scleritis - blood</subject><subject>Scleritis - diagnosis</subject><subject>Systemic diseases</subject><issn>1755-375X</issn><issn>1755-3768</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqN0MtKw0AUBuBBFFurC19AAm50kXbumdkIpXgpFLpQwV2YJCeQmiZ1JlG68xF8Rp_EqaldCIJnc87i44fzI3RK8JD4GZnaDQnDWOyhPomECFkk1f7uFk89dOTcAmNJpOSHqEcjjDVTtI-uplUDtoT2uag-3z8oDRzYdhmU8AqlC4yFAPxtGsiCogpM2hSvELi0BFs0hTtGB7kpHZxs9wA93lw_TO7C2fx2OhnPwpRrIkLNaQ5KkogTyYWWIqWJzgjVBifAowg0JjqJMpZkOdUMeCK4wSrNJKgcA2MDdNHlrmz90oJr4mXhUihLU0HdupgoogmnlPyLCqlwJLCn57_oom5t5R_ZKK6YFEx5ddmp1NbOWcjjlS2Wxq5jguNN_7HvP_7u39uzbWKbLCHbyZ_CPRh14K0oYf13Ujye33eRX6A1jSg</recordid><startdate>201609</startdate><enddate>201609</enddate><creator>Sainz‐de‐la‐Maza, Maite</creator><creator>Molins, Blanca</creator><creator>Mesquida, Marina</creator><creator>Llorenç, Victor</creator><creator>Zarranz‐Ventura, Javier</creator><creator>Sala‐Puigdollers, Anna</creator><creator>Matas, Jessica</creator><creator>Adan, Alfredo</creator><creator>Foster, C. Stephen</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>201609</creationdate><title>Interleukin‐22 serum levels are elevated in active scleritis</title><author>Sainz‐de‐la‐Maza, Maite ; Molins, Blanca ; Mesquida, Marina ; Llorenç, Victor ; Zarranz‐Ventura, Javier ; Sala‐Puigdollers, Anna ; Matas, Jessica ; Adan, Alfredo ; Foster, C. Stephen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>biomarker</topic><topic>Case-Control Studies</topic><topic>Cytokines</topic><topic>Cytokines - blood</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Interleukin-22</topic><topic>Interleukins - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Ophthalmology</topic><topic>Prospective Studies</topic><topic>scleritis</topic><topic>Scleritis - blood</topic><topic>Scleritis - diagnosis</topic><topic>Systemic diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sainz‐de‐la‐Maza, Maite</creatorcontrib><creatorcontrib>Molins, Blanca</creatorcontrib><creatorcontrib>Mesquida, Marina</creatorcontrib><creatorcontrib>Llorenç, Victor</creatorcontrib><creatorcontrib>Zarranz‐Ventura, Javier</creatorcontrib><creatorcontrib>Sala‐Puigdollers, Anna</creatorcontrib><creatorcontrib>Matas, Jessica</creatorcontrib><creatorcontrib>Adan, Alfredo</creatorcontrib><creatorcontrib>Foster, C. Stephen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Acta ophthalmologica (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sainz‐de‐la‐Maza, Maite</au><au>Molins, Blanca</au><au>Mesquida, Marina</au><au>Llorenç, Victor</au><au>Zarranz‐Ventura, Javier</au><au>Sala‐Puigdollers, Anna</au><au>Matas, Jessica</au><au>Adan, Alfredo</au><au>Foster, C. Stephen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Interleukin‐22 serum levels are elevated in active scleritis</atitle><jtitle>Acta ophthalmologica (Oxford, England)</jtitle><addtitle>Acta Ophthalmol</addtitle><date>2016-09</date><risdate>2016</risdate><volume>94</volume><issue>6</issue><spage>e395</spage><epage>e399</epage><pages>e395-e399</pages><issn>1755-375X</issn><eissn>1755-3768</eissn><abstract>Purpose
To evaluate serum cytokine profile from patients with active scleritis in a two‐centre prospective case–control study.
Methods
The serum of 20 active scleritis patients not treated with any local, periocular, or systemic immunomodulatory therapy (IMT) was analysed with multiplex assay to determine the levels of 11 cytokines interleukin (IL)‐1β, IL‐6, IL‐2, IFN‐γ, IL‐10, IL‐12p40, IL‐13, IL‐17A, IL‐5, TNF‐α, and TNF‐β, and with ELISA to determine the levels of TGF‐β1, IL‐22, and IL‐23. Twenty‐five age‐matched healthy volunteers were used as controls. In a subgroup of 13 patients with active disease, a second serum sample was obtained when the disease was inactive and levels of IL‐22 were determined. Serum IL‐22 levels from patients with active scleritis were correlated with type of scleritis (non‐necrotizing and necrotizing), degree of inflammation (0–4+ :≤2+ and >2+), and associated systemic disease.
Results
Serum levels of IL‐22 were elevated in active scleritis patients compared to controls (6.41 ± 1.52 pg/ml versus 1.93 ± 0.39 pg/ml, p = 0.012) and significantly decreased after scleritis remission with the use of IMT (p = 0.005). There was no statistical association with scleritis type, degree of inflammation, or associated systemic disease. The serum levels of other cytokines were not significantly different from controls.
Conclusion
In our study cohort, IL‐22 serum levels were significantly elevated in active scleritis patients compared to controls and decreased significantly after remission. Our results suggest that IL‐22, a T helper (Th) 17‐ and Th22‐ derived cytokine, may play a critical role in the physiopathology of scleritis.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>27009382</pmid><doi>10.1111/aos.13005</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1755-375X |
ispartof | Acta ophthalmologica (Oxford, England), 2016-09, Vol.94 (6), p.e395-e399 |
issn | 1755-375X 1755-3768 |
language | eng |
recordid | cdi_proquest_miscellaneous_1819142213 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Adult Aged Aged, 80 and over biomarker Case-Control Studies Cytokines Cytokines - blood Enzyme-Linked Immunosorbent Assay Female Health risk assessment Humans Interleukin-22 Interleukins - blood Male Middle Aged Ophthalmology Prospective Studies scleritis Scleritis - blood Scleritis - diagnosis Systemic diseases |
title | Interleukin‐22 serum levels are elevated in active scleritis |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T02%3A54%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Interleukin%E2%80%9022%20serum%20levels%20are%20elevated%20in%20active%20scleritis&rft.jtitle=Acta%20ophthalmologica%20(Oxford,%20England)&rft.au=Sainz%E2%80%90de%E2%80%90la%E2%80%90Maza,%20Maite&rft.date=2016-09&rft.volume=94&rft.issue=6&rft.spage=e395&rft.epage=e399&rft.pages=e395-e399&rft.issn=1755-375X&rft.eissn=1755-3768&rft_id=info:doi/10.1111/aos.13005&rft_dat=%3Cproquest_cross%3E1819142213%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4915-942fe861741645965c2b9d129a0be477e9019b7d3bdf293e4b54a08cd6e8f0e33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1814836538&rft_id=info:pmid/27009382&rfr_iscdi=true |